The government has injected additional funds into state owned insurers and banks to ease solvency pressures and fulfill regulatory demands.
The government injected CNY360bn ($54bn) into the country’s largest state-owned insurers and state banks, to build itself into a global financial powerhouse.
The country’s largest life insurer, China Life, will receive CNY35bn, China Taiping Insurance will get CNY7bn, China Export and Credit Insurance Corp will get CNY10bn and the People’s Insurance plans to raise up to CNY15bn through a private placement of A-shares to the Ministry of Finance. China Reinsurance will issue new A shares, with the finance ministry set to subscribe in cash for a total of CNY3bn.
The government’s capital injections push is to fortify its state financial institutions that dovetails with efforts to elevate Hong Kong’s role. Regulators have urged mainland insurers to invest in Hong Kong-listed exchange-traded funds (ETFs), bolstering the city’s status as a global financial centre.
Capital injection strengthens financial system resilience
Fitch Ratings has said that for insurers, the measures should ease rising capital pressure and strengthen risk-absorption capacity. Higher allocation to equity investment spurred by government directives and regulatory incentives have eroded insurers’ capital buffers. “The plan highlights insurers' strategic role in supporting China's financial system and reinforces our belief that the government will provide funding support to certain rated insurers if needed,” the ratings agency said in its latest non-rating action commentary.
Fitch Ratings further said that the Chinese life insurance sector's average solvency ratio fell to about 170% by end-2Q26 from 197% at end-1Q25, indicating increased pressure on insurers' capital positions. Higher equity allocations and lower interest rates have increased exposure to market volatility, asset-liability management risk and reserve requirements.
Regulators previously introduced measures to support insurers' capital positions and facilitate long-term equity investment, including favourable capital treatment for dedicated long-term investment vehicles and a 10% reduction in risk charges for certain qualifying long-term equity holdings. We also expect the planned third phase of the China Risk-Oriented Solvency System (C-ROSS Phase III) to provide further capital relief.
The announced capital injections for certain insurers are consistent with these efforts to ease capital constraints and support their participation in domestic equity markets, in line with policy objectives. Any additional capital support would reinforce this policy.
The extent of the capital benefit will depend on insurers' asset allocation decisions. Increased equity investment could increase asset risk and exposure to market volatility, which Fitch will continue to capture in its capital assessment. We will continue to assess the implications for rating sensitivities as further details, such as the timing of the capital injections, emerge.